Events & Presentations

Events & Presentations

Take a moment to view our events and clinical presentations.

Corporate Presentation | Creating New Possibilities for Patients

Presentation | Bardoxolone Methyl Overview, November 2017

November 2017

For an overview of Reata’s development program in chronic kidney disease, see Bardoxolone Methyl Overview.


Webcast | Program Update of Bardoxolone Methyl in CKD, November 2017

November 2017

Reata management provided a Program Update of Bardoxolone Methyl in CKD in a webcast teleconference call that reviewed the Phase 2 results of CARDINAL and TSUBAKI data, other pharmacologic effects of bardoxolone in CKD patients, and discussed the PHOENIX program.

For a replay of the teleconference call (MP3), please click here.


Presentation & Poster | Primary Phase 2 Analyses from CARDINAL: A Phase 2/3 Study of Bardoxolone Methyl in Patients with Alport Syndrome, American Society of Nephrology Kidney Week Meeting, November 2017


November 2017

Geoffrey A. Block, M.D., CCRI, director of clinical research at Denver Nephrology, presented, Primary Phase 2 Analyses from CARDINAL: A Phase 2/3 Study of Bardoxolone Methyl in Patients with Alport Syndrome, at the American Society of Nephrology Kidney Week 2017 Annual Meeting in New Orleans, Louisiana.

For a poster of the data, Initial Data Report from ‘CARDINAL’: A Phase 2/3 Study of
Bardoxolone Methyl in Patients with Alport Syndrome
, please click here.


Poster | Reata Pharmaceuticals at European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Madrid, Spain 2017

June 2017

Reata Pharmaceuticals exhibited the poster, A Phase 2/3 Study of Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome, at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Madrid, Spain 2017.

Presentation | Dr. David Lynch, Director of the Friedreich’s Ataxia Program at Children’s Hospital of Philadelphia, at the Patient-Focused Drug Development meeting hosted by FARA, 2017

June 2017

Reata’s results from MOXIe Part 1, a Phase 2 trial in Friedreich’s ataxia, were presented by Dr. David Lynch, Director of the Friedreich’s Ataxia Program at Children’s Hospital of Philadelphia, during the afternoon of June 2, 2017 at 3:00pm EDT, after completion of the Patient-Focused Drug Development meeting hosted by FARA: Safety, Efficacy, and Pharmacodynamics of Omav (Omaveloxolone) in Friedreich’s Ataxia Patients (MOXIe Trial): Part 1 Results.


Poster | R. James White, M.D., Ph.D., School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, at American Thoracic Society (ATS) in Washington DC, 2017

May 2017

Reata Pharmaceuticals presented interim data from extension phase of the LARIAT study of bardoxolone methyl in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD) at the annual meeting of the 2017 American Thoracic Society (ATS) in Washington DC, USA. The presentation, Interim Analysis of the Efficacy and the Safety of Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD) (The LARIAT Study), was presented by R. James White, M.D., Ph.D., from the School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY.

Poster | Greg Miller, Ph.D., Reata Pharmaceuticals Principal Scientist, at American Thoracic Society (ATS) in Washington DC, 2017

May 2017

Reata Pharmaceuticals presented the preclinical rationale for developing bardoxolone methyl for pulmonary hypertension at the annual meeting of the 2017 American Thoracic Society (ATS) in Washington DC, USA. The presentation, Bardoxolone Methyl Inhibits Proliferation of Human Pulmonary Arterial Smooth Muscle Cells Cultured Under Hypoxic Conditions, was presented by Greg Miller, Ph.D., Principal Scientist at Reata Pharmaceuticals.

Poster | R. James White, M.D., Ph.D., School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, at American College of Rheumatology (ACR) in Washington DC, 2016

November 2016

Reata Pharmaceuticals presented interim data from extension phase of the LARIAT study of bardoxolone methyl in Pulmonary Arterial Hypertension at the annual meeting of the 2016 American College of Rheumatology (ACR) in Washington DC, USA. The presentation, Bardoxolone Methyl Produces Durable Benefits in Participants with Pulmonary Arterial Hypertension: Data from an Open-Label Extension Study, was presented by R. James White, M.D., Ph.D., from the School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY.

Video | Scleroderma News Interviews Colin Meyer, M.D., at Systemic Sclerosis World Conference in Lisbon, Portugal, 2016

February 2016

Colin Meyer, M.D., Reata Pharmaceuticals’ Chief Medical Officer, talks with Scleroderma News correspondent Dr. Ana de Barros about LARIAT, a Phase 2 study of bardoxolone methyl in patients with pulmonary hypertension (PH), and CATALYST, a Phase 3 study of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) at the 4th Systemic Sclerosis World Conference in Lisbon, Portugal, from February 18-20, 2016.

LARIAT and CATALYST

Presentation | Ronald Oudiz, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA, at CHEST 2015 in Montreal, Canada

October 2015

Reata Pharmaceuticals announced initial data from the LARIAT trial evaluating bardoxolone methyl in pulmonary arterial hypertension (PAH) patients at the annual meeting of the 2015 American College of Chest Physicians (CHEST) in Montreal, Canada. The presentation, Initial Data Report from “LARIAT”: a Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background Therapy, was presented by Ronald Oudiz, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA. Dr. Oudiz is Director of the Pulmonary Hypertension Center and a Faculty Cardiologist at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Southern California.

LARIAT

Presentation | Colin Meyer, M.D., Reata Pharmaceuticals’ Chief Medical

Officer, at the International Ataxia Research Conference 2015

March 2015

Colin Meyer, M.D., Reata Pharmaceuticals’ Chief Medical Officer, delivered a presentation titled, Rationale and Design of a Clinical Study of RTA 408 in Patients with Friedreich’s Ataxia, at the International Ataxia Research Conference 2015 in Windsor, England, co-hosted by Friedreich’s Ataxia Research Alliance (FARA) and International Ataxia Research Organizations.

fara

Video | Reata Pharmaceuticals Clinical Trial in FA for RTA 408

March 2015

Reata Pharmaceuticals has launched a clinical trial in Friedreich’s ataxia (FA) for our drug RTA 408. Our Chief Medical Officer, Dr. Colin Meyer, had the opportunity to talk with the Friedreich’s Ataxia Research Alliance (FARA) about Reata and RTA 408.

fara

Presentation | Investigation of Serious Adverse Events in Bardoxolone Methyl Patients in BEACON (ERA-EDTA, June 2014)


June 2014

Colin Meyer, M.D., Reata’s Chief Medical Officer, presented a Late-Breaking Presentation at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress in Amsterdam in June 2014, Investigation of Serious Adverse Events in Bardoxolone Methyl Patients in BEACON, that discusses the clinical profile, risk factors, and likely mechanistic explanation of key adverse events uncovered in the BEACON trial.